trazodone has been researched along with Chronic Insomnia in 99 studies
Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309)
trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Trazodone and cognitive-behavioural treatment for insomnia (CBT-I) are widely used to treat patients with chronic insomnia." | 9.41 | Effect of trazodone versus cognitive-behavioural treatment on high- and slow-frequency activity during non-rapid eye movement sleep in chronic insomnia: A pilot, randomized clinical trial. ( Bixler, EO; Fang, J; Fernandez-Mendoza, J; Li, Y; Puzino, K; Vgontzas, AN, 2021) |
| "Early human pharmaco-EEG and subsequent sleep laboratory studies identified trazodone, a 5-HT(2) antagonist and 5-HT reuptake inhibitor (SARI), as an antidepressant with therapeutic effects on its target symptoms depressed mood, anxiety and insomnia." | 9.10 | Confirmation of the neurophysiologically predicted therapeutic effects of trazodone on its target symptoms depression, anxiety and insomnia by postmarketing clinical studies with a controlled-release formulation in depressed outpatients. ( Anderer, P; Arnold, O; Saletu, B; Saletu-Zyhlarz, GM, 2003) |
| "Six middle aged subjects complaining of chronic insomnia associated with dysthymia were investigated in a 2-month single blind study: a 7-day placebo treatment period, followed by a 6-week phase with increasing doses of trazodone controlled release (CR) formulation (50 mg through days 8-10; 75 mg through days 11-13; 150 mg through days 14-49) and then a final 7-day withdrawal period under placebo." | 9.07 | Clinical and polysomnographic effects of trazodone CR in chronic insomnia associated with dysthymia. ( Boselli, M; Di Giovanni, G; Parrino, L; Spaggiari, MC; Terzano, MG, 1994) |
| "A retrospective cohort study was conducted using IBM MarketScan Commercial and Medicare Supplemental Databases to identify adults with: (1) ≥1 ICD-9/ICD-10 code for depression; (2) ≥1 commonly prescribed medication for insomnia (zolpidem immediate release [IR], zolpidem extended release [ER], trazodone, or benzodiazepines); and (3) ≥12 months of eligibility before and after initiating insomnia medication." | 8.12 | Incremental health care resource use and costs among adult patients with depression and treated for insomnia with zolpidem, trazodone, or benzodiazepines. ( Amari, DT; Frech, F; Gor, D; Juday, TR; Malhotra, M; Wickwire, EM, 2022) |
| "This study aimed to examine the effects of suvorexant on delirium prevention in a real-world setting." | 7.96 | Real-World Preventive Effects of Suvorexant in Intensive Care Delirium: A Retrospective Cohort Study. ( Araki, T; Hashioka, S; Hayashida, M; Inagaki, M; Ito, T; Izuhara, HK; Izuhara, M; Kimura, T; Miura, S; Nagahama, M; Otsuki, K; Saito, Y; Sato, K; Tsuchie, K; Tsumoto, S; Wake, R, 2020) |
| "This retrospective chart review examined the relative effectiveness of fluoxetine and trazodone in relieving insomnia associated with depressive disorders in adolescents (aged 13-17 years)." | 7.69 | Trazodone is only slightly faster than fluoxetine in relieving insomnia in adolescents with depressive disorders. ( Bhatara, VS; Fogas, BS; Kallepalli, BR; Misra, LK; Tervo, RC, 1997) |
| "An additional insomnia analysis assessed whether the efficacy of TzCOAD is influenced by improvements in insomnia or baseline severity of insomnia." | 6.74 | The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder. ( Gibertini, M; Gossen, ER; Rozova, A; Sheehan, DV, 2009) |
| "Trazodone is a triazolopyridine derivative, chemically and pharmacologically unrelated to other currently available antidepressants." | 6.39 | Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. ( Fitton, A; Haria, M; McTavish, D, 1994) |
| "Antidepressant-induced jitteriness/anxiety syndrome is characterized as anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, and (hypo)mania, which appear immediately after initiation or increased dosage of an antidepressant." | 5.91 | Jitteriness/anxiety syndrome caused by coadministration of celecoxib, a selective COX-2 inhibitor, with escitalopram and trazodone in a patient with depression and spondylolisthesis. ( Kanno, M; Noto, K; Shirata, T; Suzuki, A; Yano, S, 2023) |
| "Trazodone and cognitive-behavioural treatment for insomnia (CBT-I) are widely used to treat patients with chronic insomnia." | 5.41 | Effect of trazodone versus cognitive-behavioural treatment on high- and slow-frequency activity during non-rapid eye movement sleep in chronic insomnia: A pilot, randomized clinical trial. ( Bixler, EO; Fang, J; Fernandez-Mendoza, J; Li, Y; Puzino, K; Vgontzas, AN, 2021) |
| "To compare the therapeutic effects of insomnia accompanied with depressive disorders treated by acupuncture of relieving depression and regulating mind and oral administration of Trazodone." | 5.14 | [Effect of acupuncture treatment of relieving depression and regulating mind on insomnia accompanied with depressive disorders]. ( Lai, XS; Luo, WZ; Zhang, QZ, 2010) |
| "Early human pharmaco-EEG and subsequent sleep laboratory studies identified trazodone, a 5-HT(2) antagonist and 5-HT reuptake inhibitor (SARI), as an antidepressant with therapeutic effects on its target symptoms depressed mood, anxiety and insomnia." | 5.10 | Confirmation of the neurophysiologically predicted therapeutic effects of trazodone on its target symptoms depression, anxiety and insomnia by postmarketing clinical studies with a controlled-release formulation in depressed outpatients. ( Anderer, P; Arnold, O; Saletu, B; Saletu-Zyhlarz, GM, 2003) |
| "Six middle aged subjects complaining of chronic insomnia associated with dysthymia were investigated in a 2-month single blind study: a 7-day placebo treatment period, followed by a 6-week phase with increasing doses of trazodone controlled release (CR) formulation (50 mg through days 8-10; 75 mg through days 11-13; 150 mg through days 14-49) and then a final 7-day withdrawal period under placebo." | 5.07 | Clinical and polysomnographic effects of trazodone CR in chronic insomnia associated with dysthymia. ( Boselli, M; Di Giovanni, G; Parrino, L; Spaggiari, MC; Terzano, MG, 1994) |
| " For individual adverse events that developed or worsened during therapy, more fluoxetine-treated patients reported rhinitis and tremor (p less than or equal to ." | 5.07 | Fluoxetine versus trazodone: efficacy and activating-sedating effects. ( Beasley, CM; Bosomworth, JC; Dornseif, BE; Pultz, JA; Sayler, ME, 1991) |
| " Pitolisant, a novel histamine-3 receptor antagonist/inverse agonist, gained approval for the treatment of excessive daytime sleepiness in adults with narcolepsy as well as obstructive sleep apnea." | 5.05 | New pharmacologic agents for insomnia and hypersomnia. ( Earl, DC; Van Tyle, KM, 2020) |
| "From this review, it is concluded that there are very few data to suggest that trazodone improves sleep in patients without mood disorder, though it does increase total sleep in patients with major depressive disorder." | 4.82 | The use of trazodone as a hypnotic: a critical review. ( James, SP; Mendelson, WB, 2004) |
| "A retrospective cohort study was conducted using IBM MarketScan Commercial and Medicare Supplemental Databases to identify adults with: (1) ≥1 ICD-9/ICD-10 code for depression; (2) ≥1 commonly prescribed medication for insomnia (zolpidem immediate release [IR], zolpidem extended release [ER], trazodone, or benzodiazepines); and (3) ≥12 months of eligibility before and after initiating insomnia medication." | 4.12 | Incremental health care resource use and costs among adult patients with depression and treated for insomnia with zolpidem, trazodone, or benzodiazepines. ( Amari, DT; Frech, F; Gor, D; Juday, TR; Malhotra, M; Wickwire, EM, 2022) |
| "This study aimed to examine the effects of suvorexant on delirium prevention in a real-world setting." | 3.96 | Real-World Preventive Effects of Suvorexant in Intensive Care Delirium: A Retrospective Cohort Study. ( Araki, T; Hashioka, S; Hayashida, M; Inagaki, M; Ito, T; Izuhara, HK; Izuhara, M; Kimura, T; Miura, S; Nagahama, M; Otsuki, K; Saito, Y; Sato, K; Tsuchie, K; Tsumoto, S; Wake, R, 2020) |
| "This retrospective study examines whether long-term use of trazodone, an SWS enhancer, is associated with delayed cognitive decline." | 3.91 | Long-Term Trazodone Use and Cognition: A Potential Therapeutic Role for Slow-Wave Sleep Enhancers. ( Karageorgiou, E; Krystal, AD; La, AL; Miller, BL; Neylan, TC; Vossel, KA; Walsh, CM; Yaffe, K, 2019) |
| "Guidelines for the pharmacological treatment of chronic insomnia in adults recognize that trazodone and other off-label medications are commonly prescribed despite poor evidence." | 3.91 | Prescription Medications for the Treatment of Insomnia and Risk of Suicide Attempt: a Comparative Safety Study. ( Au, A; Bishop, TM; Hur, K; Kane, C; Lavigne, JE; Pigeon, WR, 2019) |
| "This retrospective chart review examined the relative effectiveness of fluoxetine and trazodone in relieving insomnia associated with depressive disorders in adolescents (aged 13-17 years)." | 3.69 | Trazodone is only slightly faster than fluoxetine in relieving insomnia in adolescents with depressive disorders. ( Bhatara, VS; Fogas, BS; Kallepalli, BR; Misra, LK; Tervo, RC, 1997) |
| "Changes in insomnia symptoms will be evaluated throughout the study using clinically validated symptomatology questionnaires, Fitbits, and other behavioural variables." | 3.30 | Investigating the effectiveness of electronically delivered cognitive behavioural therapy (e-CBTi) compared to pharmaceutical interventions in treating insomnia: Protocol for a randomized controlled trial. ( Alavi, N; Jagayat, J; Kumar, A; Moghimi, E; Nikjoo, N; Omrani, M; Patel, C; Shirazi, A; Stephenson, C; Zhu, Y, 2023) |
| "It is common to provide insomnia patients a second treatment when the initial treatment fails, but little is known about optimal treatment sequences for different patient types." | 3.11 | Association between insomnia patients' pre-treatment characteristics and their responses to distinctive treatment sequences. ( Beaulieu-Bonneau, S; Bélanger, L; Edinger, JD; Guay, B; Ivers, H; Morin, CM; Simmons, B, 2022) |
| "One frequently reported symptom is insomnia." | 2.94 | Sleep-HD trial: short and long-term effectiveness of existing insomnia therapies for patients undergoing hemodialysis. ( Abad, K; Cukor, D; Heagerty, P; McCurry, SM; Mehrotra, R; Roumelioti, ME; Rue, T; Unruh, M, 2020) |
| "Whether insomnia with objective short sleep duration responds better to pharmacological treatment compared to CBT-I has not been examined." | 2.94 | Effects of trazodone versus cognitive behavioral therapy in the insomnia with short sleep duration phenotype: a preliminary study. ( Basta, M; Bixler, EO; Fernandez-Mendoza, J; Krishnamurthy, VB; Puzino, K; Vgontzas, AN, 2020) |
| "Chronic insomnia is a prevalent disorder associated with significant psychosocial, health, and economic impacts." | 2.82 | Sequential psychological and pharmacological therapies for comorbid and primary insomnia: study protocol for a randomized controlled trial. ( Beaulieu-Bonneau, S; Buysse, DJ; Edinger, JD; Ivers, H; Krystal, AD; Morin, CM, 2016) |
| "Trazodone has been widely prescribed for off-label use as a sleep aid." | 2.82 | Trazodone changed the polysomnographic sleep architecture in insomnia disorder: a systematic review and meta-analysis. ( Lv, T; Lyu, Y; Wu, J; Zheng, Y, 2022) |
| "Fifty-four pregnant women with insomnia were randomly assigned to trazodone, diphenhydramine, or placebo treatment." | 2.78 | Insomnia treatment in the third trimester of pregnancy reduces postpartum depression symptoms: a randomized clinical trial. ( Emamian, F; Ghadami, MR; Khazaie, H; Knight, DC; Tahmasian, M, 2013) |
| "Trazodone 50 mg was administered to participants 30 min before bedtime for 7 days in a 3-week, within-subjects, randomized, double-blind, placebo-controlled design." | 2.76 | Cognitive, psychomotor and polysomnographic effects of trazodone in primary insomniacs. ( Liguori, A; McCall, WV; Roth, AJ, 2011) |
| "The Athens Insomnia Scale (AIS), Sheehan Disability Scale (SDS), and Clinical Global Impression scale (CGI) were completed at baseline, after each month of treatment and after the first week of run-out phase." | 2.76 | Patients with insomnia and subthreshold depression show marked worsening of insomnia after discontinuation of sleep promoting medication. ( Jernajczyk, W; Wichniak, A; Wierzbicka, A, 2011) |
| "An additional insomnia analysis assessed whether the efficacy of TzCOAD is influenced by improvements in insomnia or baseline severity of insomnia." | 2.74 | The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder. ( Gibertini, M; Gossen, ER; Rozova, A; Sheehan, DV, 2009) |
| " This study assessed the effects of caffeine on sleep architecture and electroencephalography (EEG) spectrum alone and in combination with two different sleep-promoting medications." | 2.74 | Effects on sleep stages and microarchitecture of caffeine and its combination with zolpidem or trazodone in healthy volunteers. ( Hutson, PH; Ivarsson, M; Nutt, DJ; Paterson, LM; Wilson, SJ, 2009) |
| "In contrast, persistent insomnia measured both by the HRSD-17 insomnia subscale and the PSQI predicted recurrence." | 2.73 | Which symptoms predict recurrence of depression in women treated with maintenance interpersonal psychotherapy? ( Andreescu, C; Buysse, DJ; Cyranowski, JM; Dombrovski, AY; Frank, E; Houck, PR; Mallinger, AG; Mulsant, BH; Thase, ME, 2008) |
| "Cognitive behaviour therapy (CBT) of primary insomnia is frequently combined with various pharmacological treatments, including sedative antidepressants." | 2.73 | Trazodone improves the results of cognitive behaviour therapy of primary insomnia in non-depressed patients. ( Brunovsky, M; Horacek, J; Höschl, C; Krajca, V; Matousek, M; Sos, P; Zavesicka, L, 2008) |
| "The treatment with trazodone decreased the score in the AIS (13." | 2.73 | [The effectiveness of treatment with trazodone in patients with primary insomnia without and with prior history of hypnotics use]. ( Czasak, K; Jernajczyk, W; Musińska, I; Sobańska, A; Szatkowska, E; Wichniak, A; Wierzbicka, A, 2007) |
| "Insomnia is a common and disabling complaint for which there is a need for improved treatments." | 2.73 | A translational, caffeine-induced model of onset insomnia in rats and healthy volunteers. ( Hutson, PH; Ivarsson, M; Nutt, DJ; Paterson, LM; Wilson, SJ, 2007) |
| "In the treatment of insomnia, trazodone is less effective than hypnotics in the treatment of sleep onset insomnia (i." | 2.72 | Treatment of insomnia - effect of trazodone and hypnotics on sleep. ( Jarema, M; Wichniak, A; Wierzbicka, AE, 2021) |
| "Trazodone has been reported to be an effective hypnotic for patients with antidepressant-associated insomnia." | 2.71 | The effects of trazodone on sleep in patients treated with stimulant antidepressants. ( Gözükirmizi, E; Guilleminault, C; Kaynak, D; Kaynak, H, 2004) |
| " As a result, trazodone at the dosage of 50-100 mg/day improved sleep disorders, particularly at the 100 mg/day dosage." | 2.69 | Effect of trazodone in a single dose before bedtime for sleep disorders accompanied by a depressive state: dose-finding study with no concomitant use of hypnotic agent. ( Horikoshi, R; Kaneko, Y; Kumashiro, H; Mashiko, H; Niwa, S; Numata, Y; Suzuki, S; Watanabe, Y, 1999) |
| "Trazodone is an effective hypnotic for patients with antidepressant-associated insomnia." | 2.67 | Trazodone for antidepressant-associated insomnia. ( Adler, LA; Nierenberg, AA; Peselow, E; Rosenthal, M; Zornberg, G, 1994) |
| "Trazodone was effective in sleep maintenance by decreasing the number of early awakenings and it could significantly improve perceived sleep quality, although there were no significant improvements in sleep efficiency or other objective measures." | 2.58 | Trazodone for the treatment of insomnia: a meta-analysis of randomized placebo-controlled trials. ( Chen, MY; Ghadami, MR; Kuang, L; Meng, HQ; Ni, SF; Yi, XY; Zhang, L; Zhang, YQ; Zhou, XY, 2018) |
| "Antidepressant use for insomnia is widespread, but none is licensed for insomnia and the evidence for their efficacy is unclear." | 2.58 | Antidepressants for insomnia in adults. ( Baldwin, DS; Everitt, H; Lipinska, G; Malizia, AL; Manson, CC; Mayers, A; Stuart, B; Wilson, S, 2018) |
| "This article focuses on insomnia and presents a treatment algorithm for managing insomnia in older adults, along with a representative clinical case." | 2.53 | Deconstructing Chronic Low Back Pain in the Older Adult-Step by Step Evidence and Expert-Based Recommendations for Evaluation and Treatment: Part VII: Insomnia. ( Bramoweth, AD; Buysse, DJ; Gentili, A; Germain, A; Kochersberger, G; Renqvist, JG; Rodriguez, E; Rossi, MI; Weiner, DK, 2016) |
| "Insomnia in patients with alcohol dependence has increasingly become a target of treatment due to its prevalence, persistence, and associations with relapse and suicidal thoughts, as well as randomized controlled studies demonstrating efficacy with behavior therapies and non-addictive medications." | 2.52 | Assessment and treatment of insomnia in adult patients with alcohol use disorders. ( Brower, KJ, 2015) |
| "Such approach to treatment of insomnia in depressed patients protects them against dependence on hypnotic drugs." | 2.47 | [The effects of antidepressants on sleep in depressed patients with particular reference to trazodone in comparison to agomelatine, amitriptyline, doxepin, mianserine and mirtazapine]. ( Wichniak, A; Wierzbicka, A, 2011) |
| "Trazodone is an established antidepressant that is prescribed frequently as an off-label hypnotic with wide acceptance among psychiatrists." | 2.47 | Trazodone: properties and utility in multiple disorders. ( Mittur, A, 2011) |
| "Trazodone is an sedative antidepressant, acting quickly, efficiently, safely, with a small number of adverse reactions and proven effective in the treatment of insomnia." | 2.46 | [Efficacy of trazodone in the treatment of insomnia]. ( Florkowski, A; Gałecki, P; Talarowska, M, 2010) |
| "Many options are available to treat insomnia, to assist with either falling asleep (sleep onset) or maintaining sleep." | 2.44 | Therapeutic options for sleep-maintenance and sleep-onset insomnia. ( Jarvis, CI; Lynch, AM; Morin, AK, 2007) |
| "This article will review the causes of insomnia in the elderly, the approach to patient evaluation, and the nonpharmacologic and pharmacologic treatment of insomnia." | 2.43 | Insomnia in the elderly: cause, approach, and treatment. ( Gammack, JK; Kamel, NS, 2006) |
| "Search terms used were "insomnia," "behavioral therapy," and the generic names of agents commonly used to treat insomnia (the Food and Drug Administration-approved benzodiazepines and nonbenzodiazepines, trazodone, and over-the-counter agents)." | 2.43 | Diagnosis and treatment of chronic insomnia: a review. ( Benca, RM, 2005) |
| "As trazodone has been implicated in cardiac disorders, a further search was conducted using the term cardiac and trazodone." | 2.43 | A review of the evidence for the efficacy and safety of trazodone in insomnia. ( Mendelson, WB, 2005) |
| "Insomnia and daytime sleepiness are often associated with depression." | 2.42 | Daytime sleepiness and insomnia as correlates of depression. ( Fava, M, 2004) |
| "Trazodone is a triazolopyridine derivative, chemically and pharmacologically unrelated to other currently available antidepressants." | 2.39 | Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders. ( Fitton, A; Haria, M; McTavish, D, 1994) |
| "Trazodone has been shown to be safe in overdose, and the side effect profile is mild, with sedation the most common side effect." | 2.38 | Trazodone dosing regimen: experience with single daily administration. ( Fabre, LF, 1990) |
| "Antidepressant-induced jitteriness/anxiety syndrome is characterized as anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia, and (hypo)mania, which appear immediately after initiation or increased dosage of an antidepressant." | 1.91 | Jitteriness/anxiety syndrome caused by coadministration of celecoxib, a selective COX-2 inhibitor, with escitalopram and trazodone in a patient with depression and spondylolisthesis. ( Kanno, M; Noto, K; Shirata, T; Suzuki, A; Yano, S, 2023) |
| "Zolpidem was previously prescribed (73,342 adults [20." | 1.72 | Real-World Characteristics and Treatment Patterns of Patients With Insomnia Prescribed Trazodone in the United States. ( Anastassopoulos, KP; Baik, R; Bruni, O; Calisti, F; Cattaneo, A; Comandini, A; Gorini, M; Knight, T; Loreto, GD; Patel, R; Pochiero, I, 2022) |
| "While some research has found that insomnia heightens falls, health care resource utilization (HCRU) and costs, the impact of insomnia treatments on fall risk, mortality, HCRU and costs in the elderly population, which could be of substantial interest to payers, has not been fully elucidated." | 1.72 | Falls, healthcare resources and costs in older adults with insomnia treated with zolpidem, trazodone, or benzodiazepines. ( Amari, DT; Atkins, N; Frech, FH; Juday, T; Wang, W; Wickwire, EM; Wu, Z, 2022) |
| "Relative to matched controls, the insomnia-treated cohort showed higher risk of falls with greater HCRU and costs." | 1.72 | Fall Risk, Healthcare Resource Use, and Costs Among Adult Patients in the United States Treated for Insomnia with Zolpidem, Trazodone, or Benzodiazepines: A Retrospective Cohort Study. ( Amari, DT; Atkins, N; Frech, FH; Gor, D; Juday, TR; Wang, W; Wickwire, EM, 2022) |
| " This study was designed to predict the doses of trazodone to guide dosing in a clinical trial for pediatric insomnia using physiologically-based pharmacokinetic (PBPK) modeling." | 1.56 | Estimation of an Appropriate Dose of Trazodone for Pediatric Insomnia and the Potential for a Trazodone-Atomoxetine Interaction. ( Calisti, F; Chetty, M; Garofolo, F; Ke, AB; Oggianu, L; Petrucci, V; Picollo, R; Tongiani, S, 2020) |
| "Priapism is a serious urological and a medical emergency which has often been associated with psychotropic medications (including the antidepressant trazodone), use of marijuana and alcohol, and other factors." | 1.43 | Priapism: What cause: mental illness, psychotropic medications or poly-substance abuse? ( Khan, QS; Lokhande, A; Tucker, P, 2016) |
| "Trazodone is a second-generation atypical antidepressant exercising selective inhibitory action on the transport of serotonin." | 1.42 | Trazodone in the elderly: risk of extrapyramidal acute events. ( Esperança, S; Oliveira e Silva, A; Pacheco, AP; Sotto Mayor, J, 2015) |
| "Patients with cancer often experience insomnia." | 1.39 | An observational study of insomnia and nightmare treated with trazodone in patients with advanced cancer. ( Kabeshita, Y; Matsuda, Y; Murai, T; Ohno, Y; Okamoto, Y; Okazaki, N; Tanimukai, H; Tsuneto, S, 2013) |
| "Recipients with a diagnosis related to insomnia or a prescription claim for an FDA-approved drug for insomnia or trazodone were selected as the study sample." | 1.36 | Prevalence and cost of insomnia in a state Medicaid fee-for-service population based on diagnostic codes and prescription utilization. ( Roy, AN; Smith, M, 2010) |
| " Following recovery, animals were dosed with caffeine (10 mg/kg) alone or in combination with zolpidem (10 mg/kg) or trazodone (20 mg/kg)." | 1.35 | Characterisation of the effects of caffeine on sleep in the rat: a potential model of sleep disruption. ( Hutson, PH; Ivarsson, M; Nutt, DJ; Paterson, LM; Wilson, SJ, 2009) |
| "Trazodone is a unique antidepressant, which blocks the postsynaptic serotonin (5-HT) receptors, 5-HT(2A) and 5-HT(2C), and weakly inhibits presynaptic 5-HT transporters." | 1.34 | Does trazodone have a role in palliating symptoms? ( Davis, MP, 2007) |
| " The study is designated as semi-naturalistic due to the fact that, although the venlafaxine treatment regimen was strictly defined, the timing of the trazodone introduction and the dosage were determined by the clinicians." | 1.33 | Trazodone addition for insomnia in venlafaxine-treated, depressed inpatients: a semi-naturalistic study. ( Aït-Ameur, A; Bertschy, G; Ferrero, F; Muscionico, M; Osiek, C; Ragama-Pardos, E; Roth, L, 2005) |
| " Some participants expressed concern at the lack of data for this practice, particularly the absence of dose-response and tolerance information, and noted that the small amount of efficacy data available is not encouraging." | 1.32 | The treatment of chronic insomnia: drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation Unit meeting symposium. ( Buysse, DJ; Cassella, J; Mendelson, WB; Meyer, RE; Roehrs, T; Roth, T; Walsh, JK; Woods, JH, 2004) |
| "Despite the superior side effect profile of the newer antidepressants over the tricyclics and monoamine oxidase inhibitors, all newer antidepressants are associated with a wide array of side effects." | 1.31 | The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists. ( Dording, CM; Fava, M; Gordon, J; Kornbluh, R; Mischoulon, D; Nierenberg, AA; Petersen, TJ; Rosenbaum, JE, 2002) |
| "Trazodone has been used widely to treat insomnia in depressed patients." | 1.31 | Electroconvulsive therapy and cardiovascular complications in patients taking trazodone for insomnia. ( Hanson, CA; Krahn, LE; Pileggi, TS; Rummans, TA, 2001) |
| "Trazodone is a drug that acts a weak, but specific, inhibitor of the uptake of 3H-serotonin and is generally used for its antidepressant effects." | 1.29 | Trazodone: a non-hormonal alternative for neurovegetative climacteric symptoms. ( Albertazzi, P; Bonaccorsi, G; Campobasso, C; Dossi, L; Mollica, G; Pansini, F; Porto, S; Zanotti, L, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (4.04) | 18.7374 |
| 1990's | 16 (16.16) | 18.2507 |
| 2000's | 34 (34.34) | 29.6817 |
| 2010's | 27 (27.27) | 24.3611 |
| 2020's | 18 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Edinger, JD | 2 |
| Beaulieu-Bonneau, S | 2 |
| Ivers, H | 2 |
| Guay, B | 1 |
| Bélanger, L | 1 |
| Simmons, B | 1 |
| Morin, CM | 2 |
| Wichniak, A | 4 |
| Wierzbicka, AE | 1 |
| Jarema, M | 1 |
| Amari, DT | 3 |
| Juday, TR | 2 |
| Frech, FH | 2 |
| Wang, W | 2 |
| Gor, D | 2 |
| Atkins, N | 2 |
| Wickwire, EM | 3 |
| Frech, F | 1 |
| Malhotra, M | 1 |
| Juday, T | 1 |
| Wu, Z | 1 |
| Zheng, Y | 1 |
| Lv, T | 1 |
| Wu, J | 1 |
| Lyu, Y | 1 |
| Pochiero, I | 1 |
| Gorini, M | 1 |
| Comandini, A | 1 |
| Calisti, F | 2 |
| Loreto, GD | 1 |
| Cattaneo, A | 1 |
| Knight, T | 1 |
| Anastassopoulos, KP | 1 |
| Patel, R | 1 |
| Baik, R | 1 |
| Bruni, O | 1 |
| Shimizu, Y | 1 |
| Taga, M | 1 |
| Takahashi, Y | 1 |
| Yamamoto, Y | 1 |
| Masauji, T | 1 |
| Albanese, A | 1 |
| Vukelic, B | 1 |
| Ose, D | 1 |
| Taylor, E | 1 |
| Fortenberry, KT | 1 |
| Shirata, T | 1 |
| Yano, S | 1 |
| Noto, K | 1 |
| Kanno, M | 1 |
| Suzuki, A | 1 |
| Zhu, Y | 1 |
| Stephenson, C | 1 |
| Moghimi, E | 1 |
| Jagayat, J | 1 |
| Nikjoo, N | 1 |
| Kumar, A | 1 |
| Shirazi, A | 1 |
| Patel, C | 1 |
| Omrani, M | 1 |
| Alavi, N | 1 |
| Oggianu, L | 1 |
| Ke, AB | 1 |
| Chetty, M | 1 |
| Picollo, R | 1 |
| Petrucci, V | 1 |
| Garofolo, F | 1 |
| Tongiani, S | 1 |
| Vgontzas, AN | 2 |
| Puzino, K | 2 |
| Fernandez-Mendoza, J | 2 |
| Krishnamurthy, VB | 1 |
| Basta, M | 1 |
| Bixler, EO | 2 |
| Earl, DC | 1 |
| Van Tyle, KM | 1 |
| Izuhara, M | 1 |
| Izuhara, HK | 1 |
| Tsuchie, K | 1 |
| Araki, T | 1 |
| Ito, T | 1 |
| Sato, K | 1 |
| Miura, S | 1 |
| Otsuki, K | 1 |
| Nagahama, M | 1 |
| Hayashida, M | 1 |
| Hashioka, S | 1 |
| Wake, R | 1 |
| Kimura, T | 1 |
| Tsumoto, S | 1 |
| Saito, Y | 1 |
| Inagaki, M | 1 |
| Unruh, M | 1 |
| Cukor, D | 1 |
| Rue, T | 1 |
| Abad, K | 1 |
| Roumelioti, ME | 1 |
| McCurry, SM | 1 |
| Heagerty, P | 1 |
| Mehrotra, R | 1 |
| Assimon, MM | 1 |
| Flythe, JE | 1 |
| Li, Y | 1 |
| Fang, J | 1 |
| Khan, QS | 1 |
| Tucker, P | 1 |
| Lokhande, A | 1 |
| Yi, XY | 1 |
| Ni, SF | 1 |
| Ghadami, MR | 2 |
| Meng, HQ | 1 |
| Chen, MY | 1 |
| Kuang, L | 1 |
| Zhang, YQ | 1 |
| Zhang, L | 1 |
| Zhou, XY | 1 |
| Everitt, H | 1 |
| Baldwin, DS | 1 |
| Stuart, B | 1 |
| Lipinska, G | 1 |
| Mayers, A | 1 |
| Malizia, AL | 1 |
| Manson, CC | 1 |
| Wilson, S | 1 |
| Vijay, A | 1 |
| Becker, JE | 1 |
| Ross, JS | 1 |
| La, AL | 1 |
| Walsh, CM | 1 |
| Neylan, TC | 1 |
| Vossel, KA | 1 |
| Yaffe, K | 1 |
| Krystal, AD | 2 |
| Miller, BL | 1 |
| Karageorgiou, E | 1 |
| Lavigne, JE | 1 |
| Hur, K | 1 |
| Kane, C | 1 |
| Au, A | 1 |
| Bishop, TM | 1 |
| Pigeon, WR | 1 |
| Khazaie, H | 1 |
| Knight, DC | 1 |
| Emamian, F | 1 |
| Tahmasian, M | 1 |
| Osváth, P | 1 |
| Eraslan, D | 1 |
| Ertekin, E | 1 |
| Ertekin, BA | 1 |
| Oztürk, O | 1 |
| Brownlow, JA | 1 |
| Harb, GC | 1 |
| Ross, RJ | 1 |
| Brower, KJ | 2 |
| Sotto Mayor, J | 1 |
| Pacheco, AP | 1 |
| Esperança, S | 1 |
| Oliveira e Silva, A | 1 |
| Winkelman, JW | 1 |
| Buysse, DJ | 4 |
| Bramoweth, AD | 1 |
| Renqvist, JG | 1 |
| Germain, A | 1 |
| Gentili, A | 1 |
| Kochersberger, G | 1 |
| Rodriguez, E | 1 |
| Rossi, MI | 1 |
| Weiner, DK | 1 |
| Giannaccini, G | 1 |
| Masala, I | 1 |
| Palego, L | 1 |
| Betti, L | 1 |
| Pacciardi, B | 1 |
| Palagini, L | 1 |
| Luchini, F | 1 |
| Belli, S | 1 |
| Lucacchini, A | 1 |
| Mauri, M | 1 |
| Dombrovski, AY | 1 |
| Cyranowski, JM | 1 |
| Mulsant, BH | 1 |
| Houck, PR | 1 |
| Andreescu, C | 1 |
| Thase, ME | 1 |
| Mallinger, AG | 1 |
| Frank, E | 1 |
| Zavesicka, L | 1 |
| Brunovsky, M | 1 |
| Horacek, J | 1 |
| Matousek, M | 1 |
| Sos, P | 1 |
| Krajca, V | 1 |
| Höschl, C | 1 |
| Paterson, LM | 3 |
| Nutt, DJ | 3 |
| Ivarsson, M | 3 |
| Hutson, PH | 3 |
| Wilson, SJ | 3 |
| Roy, AN | 1 |
| Smith, M | 1 |
| Sheehan, DV | 1 |
| Rozova, A | 1 |
| Gossen, ER | 1 |
| Gibertini, M | 1 |
| Gałecki, P | 1 |
| Florkowski, A | 1 |
| Talarowska, M | 1 |
| Luo, WZ | 1 |
| Zhang, QZ | 1 |
| Lai, XS | 1 |
| Roth, AJ | 1 |
| McCall, WV | 1 |
| Liguori, A | 1 |
| Wierzbicka, A | 3 |
| Jernajczyk, W | 2 |
| Mittur, A | 1 |
| Clark, MS | 1 |
| Smith, PO | 1 |
| Jamieson, B | 1 |
| Chen, HC | 1 |
| Tsai, SJ | 1 |
| Tanimukai, H | 1 |
| Murai, T | 1 |
| Okazaki, N | 1 |
| Matsuda, Y | 1 |
| Okamoto, Y | 1 |
| Kabeshita, Y | 1 |
| Ohno, Y | 1 |
| Tsuneto, S | 1 |
| Dording, CM | 1 |
| Mischoulon, D | 1 |
| Petersen, TJ | 1 |
| Kornbluh, R | 1 |
| Gordon, J | 1 |
| Nierenberg, AA | 3 |
| Rosenbaum, JE | 1 |
| Fava, M | 2 |
| Le Bon, O | 1 |
| Murphy, JR | 1 |
| Staner, L | 1 |
| Hoffmann, G | 1 |
| Kormoss, N | 1 |
| Kentos, M | 1 |
| Dupont, P | 1 |
| Lion, K | 1 |
| Pelc, I | 1 |
| Verbanck, P | 1 |
| Karam-Hage, M | 1 |
| Saletu-Zyhlarz, GM | 4 |
| Anderer, P | 4 |
| Arnold, O | 1 |
| Saletu, B | 4 |
| Kaynak, H | 1 |
| Kaynak, D | 1 |
| Gözükirmizi, E | 1 |
| Guilleminault, C | 1 |
| Mendelson, WB | 3 |
| Roth, T | 1 |
| Cassella, J | 1 |
| Roehrs, T | 1 |
| Walsh, JK | 1 |
| Woods, JH | 1 |
| Meyer, RE | 1 |
| James, SP | 1 |
| Schwartz, T | 1 |
| Nihalani, N | 1 |
| Virk, S | 1 |
| Jindal, S | 1 |
| Costello, A | 1 |
| Muldoon, R | 1 |
| Azhar, N | 1 |
| Hussein, J | 1 |
| Tirmazi, S | 1 |
| Lu, BY | 1 |
| Woofter, C | 1 |
| Escalona, R | 1 |
| Bertschy, G | 1 |
| Ragama-Pardos, E | 1 |
| Muscionico, M | 1 |
| Aït-Ameur, A | 1 |
| Roth, L | 1 |
| Osiek, C | 1 |
| Ferrero, F | 1 |
| Benca, RM | 1 |
| Prause, W | 2 |
| Mandl, M | 2 |
| Aigner, M | 1 |
| Mikova, O | 1 |
| Bon, OL | 1 |
| McNeill, A | 1 |
| Simon, HB | 1 |
| Kamel, NS | 1 |
| Gammack, JK | 1 |
| Davis, MP | 1 |
| Morin, AK | 1 |
| Jarvis, CI | 1 |
| Lynch, AM | 1 |
| Tatman, J | 1 |
| Tuya, AC | 1 |
| Sobańska, A | 1 |
| Szatkowska, E | 1 |
| Czasak, K | 1 |
| Musińska, I | 1 |
| Heinzer, RC | 1 |
| White, DP | 1 |
| Jordan, AS | 1 |
| Lo, YL | 1 |
| Dover, L | 1 |
| Stevenson, K | 1 |
| Malhotra, A | 1 |
| Parrino, L | 1 |
| Spaggiari, MC | 1 |
| Boselli, M | 1 |
| Di Giovanni, G | 1 |
| Terzano, MG | 1 |
| Balon, R | 1 |
| Forster, P | 1 |
| King, J | 1 |
| Adler, LA | 1 |
| Peselow, E | 1 |
| Zornberg, G | 1 |
| Rosenthal, M | 1 |
| Haria, M | 1 |
| Fitton, A | 1 |
| McTavish, D | 1 |
| Pansini, F | 1 |
| Albertazzi, P | 1 |
| Bonaccorsi, G | 1 |
| Zanotti, L | 1 |
| Porto, S | 1 |
| Dossi, L | 1 |
| Campobasso, C | 1 |
| Mollica, G | 1 |
| Bhatara, VS | 2 |
| Kallepalli, BR | 2 |
| Misra, LK | 2 |
| Awadallah, S | 1 |
| Fogas, BS | 1 |
| Tervo, RC | 1 |
| Mashiko, H | 1 |
| Niwa, S | 1 |
| Kumashiro, H | 1 |
| Kaneko, Y | 1 |
| Suzuki, S | 1 |
| Numata, Y | 1 |
| Horikoshi, R | 1 |
| Watanabe, Y | 1 |
| Haffmans, PM | 1 |
| Vos, MS | 1 |
| Krahn, LE | 1 |
| Hanson, CA | 1 |
| Pileggi, TS | 1 |
| Rummans, TA | 1 |
| Warner, MD | 1 |
| Dorn, MR | 1 |
| Peabody, CA | 1 |
| Abu-Bakr, MH | 2 |
| Semler, B | 1 |
| Decker, K | 1 |
| Parapatics, S | 1 |
| Tschida, U | 1 |
| Winkler, A | 1 |
| Gruber, G | 1 |
| Strobl, R | 1 |
| Gollner, D | 1 |
| Beasley, CM | 1 |
| Dornseif, BE | 1 |
| Pultz, JA | 1 |
| Bosomworth, JC | 1 |
| Sayler, ME | 1 |
| Scharf, MB | 1 |
| Sachais, BA | 1 |
| Ware, JC | 1 |
| Pittard, JT | 1 |
| Fabre, LF | 2 |
| Metz, A | 1 |
| Shader, RI | 1 |
| Jacobsen, FM | 1 |
| Liebowitz, NR | 1 |
| el-Mallakh, RS | 1 |
| Keck, PE | 1 |
| Menza, MA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sequenced Therapies for Comorbid and Primary Insomnias[NCT01651442] | 211 participants (Actual) | Interventional | 2012-08-01 | Completed | |||
| Efficacy of Trazodone vs. Cognitive Behavioral Therapy in Patients With Chronic Insomnia Associated With Objective Short Sleep Duration[NCT01348542] | 24 participants (Actual) | Interventional | 2011-04-30 | Completed | |||
| Short and Long-Term Effectiveness of Existing Insomnia Therapies for Patients Undergoing Hemodialysis (Sleep-HD)[NCT03534284] | Phase 3 | 126 participants (Actual) | Interventional | 2018-09-19 | Completed | ||
| [NCT05753943] | 0 participants | Expanded Access | No longer available | ||||
| Maintenance Psychotherapies in Recurrent Depression: Study II[NCT00227981] | 93 participants | Interventional | 1995-03-31 | Completed | |||
| Music to Improve Sleep Quality in Adults With Depression and Insomnia: a Randomized Controlled Trial Using Mixed Methods[NCT03676491] | 112 participants (Actual) | Interventional | 2018-05-23 | Completed | |||
| Efficacy of Cranial Manual Therapy in the Treatment of Chronic Insomnia Disorder[NCT05257317] | 50 participants (Anticipated) | Interventional | 2022-02-28 | Recruiting | |||
| Evaluation of the Benefits of Individualized Advice Administration on Quality of Sleep for the Elderly Living at Home Prospective, Monocentric and Open Study[NCT03594851] | 45 participants (Actual) | Interventional | 2018-01-08 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Insomnia Severity Index (ISI) is a self-report questionnaire assessing the nature, severity, and impact of insomnia. Remission is determined to be a score less-than 8. (NCT01651442)
Timeframe: 6 weeks, 12 weeks, 3 months, 6 months, 9 months & 12 months
| Intervention | percent remitted (Number) |
|---|---|
| Non-drug Sleep Therapy 1 | 40.00 |
| Sleep Medication 1 | 34.94 |
| Sleep Medication 1 Plus Non-drug Sleep Therapy 1 | 37.04 |
| Sleep Medication 1 Plus Sleep Medication 2 | 48.15 |
| Non-drug Sleep Therapy 1 Plus Non-drug Sleep Therapy 1 | 44.44 |
| Non-drug Sleep Therapy 1 Plus Sleep Medication 1 | 55.56 |
The Insomnia Severity Index (ISI) was used to measure the change in severity of sleep disturbance at baseline to post treatment (3 months). The ISI is composed of 7 items each rated on a scale of 0-4. The total score was calculated by adding the individual item scores. The total ISI scale score ranged from 0-28 with higher total scores indicating a higher severity of insomnia symptoms. (NCT01348542)
Timeframe: Baseline to Post Treatment (3 months)
| Intervention | score on a scale (Mean) |
|---|---|
| Trazodone | -12.29 |
| Cognitive Behavioral Therapy | -10.75 |
The Insomnia Severity Index (ISI) was used to measure the change in severity of sleep disturbance at baseline to Follow Up (9 months). The ISI is composed of 7 items each rated on a scale of 0-4. The total score was calculated by adding the individual item scores. The total ISI scale score ranged from 0-28 with higher total scores indicating a higher severity of insomnia symptoms. (NCT01348542)
Timeframe: Baseline to follow up (9 months)
| Intervention | score on a scale (Mean) |
|---|---|
| Trazodone | -13.29 |
| Cognitive Behavioral Therapy | -10.38 |
Actigraphy (ad libitum time in bed) will be used to measure sleep duration at baseline and follow up (9 months) (NCT01348542)
Timeframe: Baseline to follow up (9 months)
| Intervention | minutes (Mean) |
|---|---|
| Trazodone | 50.35 |
| Cognitive Behavioral Therapy | -7.56 |
Actigraphy (ad libitum time in bed) will be used to measure sleep duration at baseline and Post Treatment (3 months) (NCT01348542)
Timeframe: Baseline to Post Treatment (3 months)
| Intervention | minutes (Mean) |
|---|---|
| Trazodone | 51.01 |
| Cognitive Behavioral Therapy | -11.73 |
Polysomnography (8 hours fixed time in bed) will be used to measure sleep duration at baseline and follow up (9 months) (NCT01348542)
Timeframe: Baseline to follow up (9 months)
| Intervention | minutes (Mean) |
|---|---|
| Trazodone | 51.78 |
| Cognitive Behavioral Therapy | 32.36 |
Polysomnography (8 hours fixed time in bed) will be used to measure sleep duration at baseline and post treatment (3 months) (NCT01348542)
Timeframe: Baseline to Post Treatment (3 months)
| Intervention | minutes (Mean) |
|---|---|
| Trazodone | 28.95 |
| Cognitive Behavioral Therapy | 38.91 |
23 reviews available for trazodone and Chronic Insomnia
| Article | Year |
|---|---|
Treatment of insomnia - effect of trazodone and hypnotics on sleep.
Topics: Humans; Hypnotics and Sedatives; Sleep; Sleep Initiation and Maintenance Disorders; Sleep Quality; T | 2021 |
Trazodone changed the polysomnographic sleep architecture in insomnia disorder: a systematic review and meta-analysis.
Topics: Arousal; Humans; Lipopolysaccharides; Randomized Controlled Trials as Topic; Sleep; Sleep Initiation | 2022 |
New pharmacologic agents for insomnia and hypersomnia.
Topics: Azepines; Carbamates; Dementia; Disorders of Excessive Somnolence; GABA-A Receptor Agonists; Humans; | 2020 |
Trazodone for the treatment of insomnia: a meta-analysis of randomized placebo-controlled trials.
Topics: Humans; Randomized Controlled Trials as Topic; Selective Serotonin Reuptake Inhibitors; Self Report; | 2018 |
Antidepressants for insomnia in adults.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Fluoxetine; Humans; Mianserin; Parox | 2018 |
[Current treatment of depression and agitation in the elderly -- clinical use of trazodone].
Topics: Aged; Aged, 80 and over; Anti-Anxiety Agents; Antidepressive Agents; Antidepressive Agents, Second-G | 2013 |
Treatment of Sleep Disturbances in Post-Traumatic Stress Disorder: A Review of the Literature.
Topics: Antipsychotic Agents; Cognitive Behavioral Therapy; Dreams; Eye Movement Desensitization Reprocessin | 2015 |
Assessment and treatment of insomnia in adult patients with alcohol use disorders.
Topics: Acamprosate; Alcohol Deterrents; Alcoholism; Amines; Anti-Anxiety Agents; Anticonvulsants; Antipsych | 2015 |
CLINICAL PRACTICE. Insomnia Disorder.
Topics: Aged; Antidepressive Agents; Cognitive Behavioral Therapy; Female; Humans; Hypnotics and Sedatives; | 2015 |
Deconstructing Chronic Low Back Pain in the Older Adult-Step by Step Evidence and Expert-Based Recommendations for Evaluation and Treatment: Part VII: Insomnia.
Topics: Aged; Algorithms; Chronic Pain; Cognitive Behavioral Therapy; Delphi Technique; Expert Testimony; Hu | 2016 |
[Efficacy of trazodone in the treatment of insomnia].
Topics: Antidepressive Agents, Second-Generation; Depression; Humans; Sleep Initiation and Maintenance Disor | 2010 |
[The effects of antidepressants on sleep in depressed patients with particular reference to trazodone in comparison to agomelatine, amitriptyline, doxepin, mianserine and mirtazapine].
Topics: Amitriptyline; Antidepressive Agents; Depression; Doxepin; Humans; Mianserin; Mirtazapine; Sleep; Sl | 2011 |
Trazodone: properties and utility in multiple disorders.
Topics: Animals; Anxiety Disorders; Chronic Pain; Cognition Disorders; Depressive Disorder; Humans; Mental D | 2011 |
The use of trazodone as a hypnotic: a critical review.
Topics: Aged; Arrhythmias, Cardiac; Clinical Trials as Topic; Comorbidity; Depressive Disorder; Humans; Hypn | 2004 |
Daytime sleepiness and insomnia as correlates of depression.
Topics: Antidepressive Agents; Benzhydryl Compounds; Bupropion; Comorbidity; Depressive Disorder; Disorders | 2004 |
Diagnosis and treatment of chronic insomnia: a review.
Topics: Acetamides; Benzodiazepines; Diagnostic and Statistical Manual of Mental Disorders; Health Status; H | 2005 |
A review of the evidence for the efficacy and safety of trazodone in insomnia.
Topics: Adult; Age Factors; Aged; Antidepressive Agents, Second-Generation; Clinical Trials as Topic; Depres | 2005 |
Insomnia in the elderly: cause, approach, and treatment.
Topics: Acetamides; Aged; Aging; Antidepressive Agents; Azabicyclo Compounds; Behavior Therapy; Benzodiazepi | 2006 |
Therapeutic options for sleep-maintenance and sleep-onset insomnia.
Topics: Antidepressive Agents, Second-Generation; Histamine H1 Antagonists; Humans; Hypnotics and Sedatives; | 2007 |
Definitive treatment of patients with serious mental disorders in an emergency service, Part I.
Topics: Antidepressive Agents; Anxiety Disorders; Depressive Disorder; Emergency Services, Psychiatric; Hosp | 1994 |
Trazodone. A review of its pharmacology, therapeutic use in depression and therapeutic potential in other disorders.
Topics: Aged; Aged, 80 and over; Depression; Female; Humans; Male; Middle Aged; Sleep Initiation and Mainten | 1994 |
Trazodone dosing regimen: experience with single daily administration.
Topics: Circadian Rhythm; Depressive Disorder; Drug Administration Schedule; Half-Life; Humans; Sleep; Sleep | 1990 |
United States experience and perspectives with trazodone.
Topics: Aged; Bulimia; Chronic Disease; Clinical Trials as Topic; Depressive Disorder; Female; Humans; Male; | 1989 |
35 trials available for trazodone and Chronic Insomnia
| Article | Year |
|---|---|
Association between insomnia patients' pre-treatment characteristics and their responses to distinctive treatment sequences.
Topics: Adult; Cognitive Behavioral Therapy; Female; Humans; Male; Middle Aged; Sleep; Sleep Initiation and | 2022 |
Investigating the effectiveness of electronically delivered cognitive behavioural therapy (e-CBTi) compared to pharmaceutical interventions in treating insomnia: Protocol for a randomized controlled trial.
Topics: Cognitive Behavioral Therapy; Humans; Pharmaceutical Preparations; Randomized Controlled Trials as T | 2023 |
Effects of trazodone versus cognitive behavioral therapy in the insomnia with short sleep duration phenotype: a preliminary study.
Topics: Adult; Cognitive Behavioral Therapy; Female; Humans; Hypothalamo-Hypophyseal System; Male; Middle Ag | 2020 |
Sleep-HD trial: short and long-term effectiveness of existing insomnia therapies for patients undergoing hemodialysis.
Topics: Anti-Anxiety Agents; Cognitive Behavioral Therapy; Comparative Effectiveness Research; Humans; Kidne | 2020 |
Effect of trazodone versus cognitive-behavioural treatment on high- and slow-frequency activity during non-rapid eye movement sleep in chronic insomnia: A pilot, randomized clinical trial.
Topics: Cognition; Cognitive Behavioral Therapy; Electroencephalography; Female; Humans; Male; Polysomnograp | 2021 |
Insomnia treatment in the third trimester of pregnancy reduces postpartum depression symptoms: a randomized clinical trial.
Topics: Actigraphy; Adult; Antidepressive Agents, Second-Generation; Depression; Depression, Postpartum; Dip | 2013 |
Treatment of insomnia with hypnotics resulting in improved sexual functioning in post-menopausal women.
Topics: Azabicyclo Compounds; Female; Humans; Hypnotics and Sedatives; Piperazines; Postmenopause; Selective | 2014 |
Sequential psychological and pharmacological therapies for comorbid and primary insomnia: study protocol for a randomized controlled trial.
Topics: Adult; Affect; Clinical Protocols; Cognitive Behavioral Therapy; Colorado; Combined Modality Therapy | 2016 |
Which symptoms predict recurrence of depression in women treated with maintenance interpersonal psychotherapy?
Topics: Adult; Affect; Anxiety Disorders; Combined Modality Therapy; Comorbidity; Depressive Disorder, Major | 2008 |
Trazodone improves the results of cognitive behaviour therapy of primary insomnia in non-depressed patients.
Topics: Adult; Antidepressive Agents, Second-Generation; Cognitive Behavioral Therapy; Combined Modality The | 2008 |
Effects on sleep stages and microarchitecture of caffeine and its combination with zolpidem or trazodone in healthy volunteers.
Topics: Adult; Caffeine; Central Nervous System Stimulants; Cross-Over Studies; Double-Blind Method; Electro | 2009 |
The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Anxiety; Delayed-Action Prepa | 2009 |
[Effect of acupuncture treatment of relieving depression and regulating mind on insomnia accompanied with depressive disorders].
Topics: Acupuncture Therapy; Adult; Depressive Disorder; Female; Humans; Male; Middle Aged; Sleep Initiation | 2010 |
Cognitive, psychomotor and polysomnographic effects of trazodone in primary insomniacs.
Topics: Adult; Cognition; Double-Blind Method; Female; Humans; Hypnotics and Sedatives; Male; Memory; Neurop | 2011 |
Patients with insomnia and subthreshold depression show marked worsening of insomnia after discontinuation of sleep promoting medication.
Topics: Actigraphy; Adult; Aged; Delayed-Action Preparations; Dysthymic Disorder; Female; Humans; Hypnotics | 2011 |
Double-blind, placebo-controlled study of the efficacy of trazodone in alcohol post-withdrawal syndrome: polysomnographic and clinical evaluations.
Topics: Adolescent; Adult; Aged; Alcoholism; Antidepressive Agents, Second-Generation; Central Nervous Syste | 2003 |
Open pilot study of gabapentin versus trazodone to treat insomnia in alcoholic outpatients.
Topics: Acetates; Alcoholism; Amines; Antidepressive Agents, Second-Generation; Cyclohexanecarboxylic Acids; | 2003 |
Confirmation of the neurophysiologically predicted therapeutic effects of trazodone on its target symptoms depression, anxiety and insomnia by postmarketing clinical studies with a controlled-release formulation in depressed outpatients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Anxiety; Bipol | 2003 |
The effects of trazodone on sleep in patients treated with stimulant antidepressants.
Topics: Adult; Cross-Over Studies; Depressive Disorder, Major; Double-Blind Method; Electromyography; Electr | 2004 |
"A comparison of the effectiveness of two hypnotic agents for the treatment of insomnia".
Topics: Acetamides; Administration, Oral; Adolescent; Adult; Aged; Drug Monitoring; Female; Humans; Hypnotic | 2004 |
Insomnia in somatoform pain disorder: sleep laboratory studies on differences to controls and acute effects of trazodone, evaluated by the Somnolyzer 24 x 7 and the Siesta database.
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Case-Control Studies; Cross-Over Studies; Databases as | 2005 |
Low-dose trazodone effective in insomnia.
Topics: Anti-Anxiety Agents; Dose-Response Relationship, Drug; Humans; Sleep Initiation and Maintenance Diso | 2005 |
A translational, caffeine-induced model of onset insomnia in rats and healthy volunteers.
Topics: Adult; Animals; Caffeine; Central Nervous System Stimulants; Cross-Over Studies; Disease Models, Ani | 2007 |
[The effectiveness of treatment with trazodone in patients with primary insomnia without and with prior history of hypnotics use].
Topics: Aged; Antidepressive Agents; Female; Humans; Hypnotics and Sedatives; Male; Medical History Taking; | 2007 |
Trazodone increases arousal threshold in obstructive sleep apnoea.
Topics: Adult; Arousal; Female; Humans; Male; Middle Aged; Polysomnography; Sleep Apnea, Obstructive; Sleep | 2008 |
Clinical and polysomnographic effects of trazodone CR in chronic insomnia associated with dysthymia.
Topics: Adult; Chronic Disease; Delayed-Action Preparations; Depressive Disorder; Female; Humans; Male; Midd | 1994 |
Trazodone for antidepressant-associated insomnia.
Topics: Adult; Bupropion; Confidence Intervals; Depressive Disorder; Dose-Response Relationship, Drug; Doubl | 1994 |
Effect of trazodone in a single dose before bedtime for sleep disorders accompanied by a depressive state: dose-finding study with no concomitant use of hypnotic agent.
Topics: Adult; Antidepressive Agents, Second-Generation; Depressive Disorder; Dose-Response Relationship, Dr | 1999 |
The effects of trazodone on sleep disturbances induced by brofaromine.
Topics: Dose-Response Relationship, Drug; Double-Blind Method; Electroencephalography; Follow-Up Studies; Hu | 1999 |
Survey on the usefulness of trazodone in patients with PTSD with insomnia or nightmares.
Topics: Adult; Antidepressive Agents, Second-Generation; Dreams; Humans; Male; Middle Aged; Psychiatric Stat | 2001 |
Insomnia related to dysthymia: polysomnographic and psychometric comparison with normal controls and acute therapeutic trials with trazodone.
Topics: Adult; Aged; Dysthymic Disorder; Female; Humans; Male; Middle Aged; Polysomnography; Psychometrics; | 2001 |
Insomnia in depression: differences in objective and subjective sleep and awakening quality to normal controls and acute effects of trazodone.
Topics: Adult; Aged; Antidepressive Agents; Cross-Over Studies; Depressive Disorder; Female; Humans; Male; M | 2002 |
Fluoxetine versus trazodone: efficacy and activating-sedating effects.
Topics: Adult; Akathisia, Drug-Induced; Ambulatory Care; Anxiety; Depressive Disorder; Dizziness; Double-Bli | 1991 |
Increased deep sleep after trazodone use: a double-blind placebo-controlled study in healthy young adults.
Topics: Adolescent; Adult; Double-Blind Method; Galvanic Skin Response; Humans; Male; Placebos; Sleep; Sleep | 1990 |
United States experience and perspectives with trazodone.
Topics: Aged; Bulimia; Chronic Disease; Clinical Trials as Topic; Depressive Disorder; Female; Humans; Male; | 1989 |
42 other studies available for trazodone and Chronic Insomnia
| Article | Year |
|---|---|
Fall Risk, Healthcare Resource Use, and Costs Among Adult Patients in the United States Treated for Insomnia with Zolpidem, Trazodone, or Benzodiazepines: A Retrospective Cohort Study.
Topics: Adolescent; Adult; Aged; Benzodiazepines; Cohort Studies; Health Care Costs; Humans; Medicare; Patie | 2022 |
Incremental health care resource use and costs among adult patients with depression and treated for insomnia with zolpidem, trazodone, or benzodiazepines.
Topics: Adult; Aged; Benzodiazepines; Delivery of Health Care; Depression; Female; Health Care Costs; Humans | 2022 |
Falls, healthcare resources and costs in older adults with insomnia treated with zolpidem, trazodone, or benzodiazepines.
Topics: Accidental Falls; Aged; Benzodiazepines; Delivery of Health Care; Female; Health Care Costs; Humans; | 2022 |
Real-World Characteristics and Treatment Patterns of Patients With Insomnia Prescribed Trazodone in the United States.
Topics: Adult; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; Child; Cohort | 2022 |
Risk assessment of accidental falls in patients taking trazodone, quetiapine, or risperidone for insomnia: A single-center, case-control study.
Topics: Accidental Falls; Case-Control Studies; Child; Humans; Quetiapine Fumarate; Risk Assessment; Risperi | 2022 |
Is Trazodone Effective and Safe for Treating Insomnia?
Topics: Antidepressive Agents, Second-Generation; Humans; Sleep; Sleep Initiation and Maintenance Disorders; | 2023 |
Jitteriness/anxiety syndrome caused by coadministration of celecoxib, a selective COX-2 inhibitor, with escitalopram and trazodone in a patient with depression and spondylolisthesis.
Topics: Antidepressive Agents; Anxiety; Celecoxib; Cyclooxygenase 2 Inhibitors; Escitalopram; Female; Humans | 2023 |
Estimation of an Appropriate Dose of Trazodone for Pediatric Insomnia and the Potential for a Trazodone-Atomoxetine Interaction.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Atomoxetine Hydrochloride; Child; Child, Presc | 2020 |
Real-World Preventive Effects of Suvorexant in Intensive Care Delirium: A Retrospective Cohort Study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Azepines; Child; Child, Preschool; Critical Care; Deliri | 2020 |
Zolpidem Versus Trazodone Initiation and the Risk of Fall-Related Fractures among Individuals Receiving Maintenance Hemodialysis.
Topics: Accidental Falls; Aged; Cognitive Dysfunction; Dizziness; Drug Prescriptions; Female; Fractures, Bon | 2020 |
Priapism: What cause: mental illness, psychotropic medications or poly-substance abuse?
Topics: Adrenergic alpha-1 Receptor Antagonists; Depressive Disorder, Major; Hepatitis C; Humans; Male; Midd | 2016 |
Patterns and predictors of off-label prescription of psychiatric drugs.
Topics: Adult; Aged; Antipsychotic Agents; Bipolar Disorder; Citalopram; Cross-Sectional Studies; Drug Presc | 2018 |
Long-Term Trazodone Use and Cognition: A Potential Therapeutic Role for Slow-Wave Sleep Enhancers.
Topics: Aged; Alzheimer Disease; Antidepressive Agents, Second-Generation; Case-Control Studies; Cognition; | 2019 |
Prescription Medications for the Treatment of Insomnia and Risk of Suicide Attempt: a Comparative Safety Study.
Topics: Adult; Female; Humans; Male; Middle Aged; Off-Label Use; Risk Assessment; Sleep Aids, Pharmaceutical | 2019 |
Trazodone in the elderly: risk of extrapyramidal acute events.
Topics: Aged, 80 and over; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Basal Ganglia Dise | 2015 |
Melatonin and pro-hypnotic effectiveness of the antidepressant Trazodone: A preliminary evaluation in insomniac mood-disorder patients.
Topics: Adult; Antidepressive Agents; Chromatography, High Pressure Liquid; Female; Humans; Hypnotics and Se | 2016 |
Characterisation of the effects of caffeine on sleep in the rat: a potential model of sleep disruption.
Topics: Animals; Body Temperature; Caffeine; Central Nervous System Stimulants; Disease Models, Animal; Elec | 2009 |
Prevalence and cost of insomnia in a state Medicaid fee-for-service population based on diagnostic codes and prescription utilization.
Topics: Adolescent; Adult; Anti-Anxiety Agents; Child; Child, Preschool; Comorbidity; Diagnosis-Related Grou | 2010 |
FPIN's clinical inquiries: Antidepressants for the treatment of insomnia in patients with depression.
Topics: Amitriptyline; Antidepressive Agents; Antidepressive Agents, Tricyclic; Depression; Dose-Response Re | 2011 |
Trazodone-induced severe headache.
Topics: Adult; Anti-Anxiety Agents; Depressive Disorder, Major; Headache; Humans; Male; Sleep Initiation and | 2011 |
Drugs for insomnia.
Topics: Benzodiazepines; Drug Interactions; Histamine Antagonists; Humans; Indenes; Pyridines; Sleep Initiat | 2012 |
An observational study of insomnia and nightmare treated with trazodone in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Dreams; Female; Humans; Hy | 2013 |
The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists.
Topics: Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Bupropion; Critical Pathways; Dat | 2002 |
The treatment of chronic insomnia: drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation Unit meeting symposium.
Topics: Antidepressive Agents, Second-Generation; Chronic Disease; Depressive Disorder, Major; Dose-Response | 2004 |
A case of prolonged peyote-induced psychosis resolved by sleep.
Topics: Drug Overdose; Hallucinogens; Humans; Indians, North American; Male; Mescaline; Middle Aged; Psychos | 2004 |
Trazodone addition for insomnia in venlafaxine-treated, depressed inpatients: a semi-naturalistic study.
Topics: Adult; Chi-Square Distribution; Cyclohexanols; Depressive Disorder; Drug Therapy, Combination; Femal | 2005 |
Chorea induced by low-dose trazodone.
Topics: Aged; Antidepressive Agents, Second-Generation; Chorea; Diagnosis, Differential; Dose-Response Relat | 2006 |
On call. I am 47 years old and I've always been healthy. My main problem is insomnia. Sleeping pills don't work well, and they make me feel groggy. Finally, my doctor gave me a prescription for Desyrel, and he seems to have hit the bull's-eye. I've been s
Topics: Antidepressive Agents, Second-Generation; Humans; Male; Priapism; Sleep Initiation and Maintenance D | 2006 |
Does trazodone have a role in palliating symptoms?
Topics: Antidepressive Agents, Second-Generation; Depression; Drug Interactions; Fluoxetine; Humans; Neoplas | 2007 |
A parent's nightmare.
Topics: Adolescent; Adult; Chronotherapy; Headache; Humans; Hypnotics and Sedatives; Male; Parents; Pyridine | 2005 |
The management of insomnia in the older adult.
Topics: Aged; Aged, 80 and over; Anti-Anxiety Agents; Antidepressive Agents; Baths; Exercise; Humans; Hypnot | 2007 |
Sleep terror disorder and insomnia treated with trazodone: a case report.
Topics: Child; Female; Humans; Hydroxyzine; Imipramine; Sleep Initiation and Maintenance Disorders; Sleep Wa | 1994 |
Trazodone: a non-hormonal alternative for neurovegetative climacteric symptoms.
Topics: Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Anxiety; Climacteric; Contraindicatio | 1995 |
A possible clonidine-trazodone-dextroamphetamine interaction in a 12-year-old boy.
Topics: Antihypertensive Agents; Bradycardia; Central Nervous System Stimulants; Child; Clonidine; Conscious | 1996 |
Trazodone is only slightly faster than fluoxetine in relieving insomnia in adolescents with depressive disorders.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Depressive Disorder; Female; Fluoxetine; Human | 1997 |
Electroconvulsive therapy and cardiovascular complications in patients taking trazodone for insomnia.
Topics: Adult; Cardiovascular Diseases; Case-Control Studies; Comorbidity; Confidence Intervals; Depressive | 2001 |
Sleep laboratory evaluation of the effects and efficacy of trazodone in depressed insomniac patients.
Topics: Adult; Depressive Disorder; Female; Humans; Male; Psychiatric Status Rating Scales; Single-Blind Met | 1990 |
Adverse interactions encountered when using trazodone to treat insomnia associated with fluoxetine.
Topics: Adult; Depression; Drug Interactions; Female; Fluoxetine; Humans; Sleep Initiation and Maintenance D | 1990 |
Low-dose trazodone as a hypnotic in patients treated with MAOIs and other psychotropics: a pilot study.
Topics: Administration, Oral; Adult; Bipolar Disorder; Depressive Disorder; Female; Humans; Male; Middle Age | 1990 |
Trazodone for the treatment of anxiety symptoms in substance abusers.
Topics: Adult; Alcoholism; Anxiety Disorders; Combat Disorders; Humans; Male; Middle Aged; Sleep Initiation | 1989 |
Management of monoamine oxidase inhibitor-associated insomnia with trazodone.
Topics: Adult; Aged; Depressive Disorder; Dose-Response Relationship, Drug; Drug Therapy, Combination; Femal | 1989 |
Withdrawal syndrome in a depressed patient treated with trazodone.
Topics: Adult; Anxiety Disorders; Depersonalization; Depressive Disorder; Dreams; Humans; Male; Sleep Initia | 1986 |